APRE Latest Press Releases

-- October 16, 2026 --

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology Globe Newswire 8:30 AM

-- October 5, 2026 --

Aprea Therapeutics to Present at October Conferences Globe Newswire 8:30 AM

-- September 22, 2026 --

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium Globe Newswire 8:30 AM

-- September 10, 2026 --

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 8:00 AM

-- August 28, 2026 --

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs Globe Newswire 8:15 AM

-- August 12, 2026 --

Aprea Therapeutics Announces Second Quarter 2026 Financial Results Globe Newswire 8:30 AM

-- August 3, 2026 --

Lipocine Appoints Michael J. Grissinger to Board of Directors PRNewswire 8:00 AM

-- July 30, 2026 --

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 Globe Newswire 8:00 AM

-- June 22, 2026 --

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology Globe Newswire 8:30 AM

-- June 1, 2026 --

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes